109 related articles for article (PubMed ID: 4020410)
1. Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report.
Quesada JR; Swanson DA; Gutterman JU
J Clin Oncol; 1985 Aug; 3(8):1086-92. PubMed ID: 4020410
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
3. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
4. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
Figlin RA; deKernion JB; Maldazys J; Sarna G
Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
[TBL] [Abstract][Full Text] [Related]
5. Treatment of renal cell carcinoma with daily low-dose alpha-interferon.
Marshall ME; Simpson W; Butler K; Fried A; Fer M
J Biol Response Mod; 1989 Oct; 8(5):453-61. PubMed ID: 2795090
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.
Quesada JR; Rios A; Swanson D; Trown P; Gutterman JU
J Clin Oncol; 1985 Nov; 3(11):1522-8. PubMed ID: 4056843
[TBL] [Abstract][Full Text] [Related]
7. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F
J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
Hutson TE; Molto L; Mekhail T; Elson P; Finke J; Tannenbaum C; Borden E; Dreicer R; Olencki T; Bukowski RM
Clin Cancer Res; 2003 Apr; 9(4):1354-60. PubMed ID: 12684404
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.
Vugrin D; Hood L; Taylor W; Laszlo J
Cancer Treat Rep; 1985; 69(7-8):817-20. PubMed ID: 4016792
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma.
Buzaid AC; Robertone A; Kisala C; Salmon SE
J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
12. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
[TBL] [Abstract][Full Text] [Related]
14. Treatment of metastatic renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
Kotake T; Kinouchi T; Saiki S; Kuroda M; Miki T; Kiyohara H; Usami M
Jpn J Clin Oncol; 1991 Feb; 21(1):46-51. PubMed ID: 2067120
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma: antitumor effects of leukocyte interferon.
Quesada JR; Swanson DA; Trindade A; Gutterman JU
Cancer Res; 1983 Feb; 43(2):940-7. PubMed ID: 6336662
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.
Kirkwood JM; Harris JE; Vera R; Sandler S; Fischer DS; Khandekar J; Ernstoff MS; Gordon L; Lutes R; Bonomi P
Cancer Res; 1985 Feb; 45(2):863-71. PubMed ID: 3881175
[TBL] [Abstract][Full Text] [Related]
17. [The treatment of renal cell carcinoma with recombinant human leukocyte interferon].
Kawamura J; Yamauchi T; Hashimura T; Yoshida O; Kohnami T; Tomoyoshi T; Ogura K; Fukuyama T; Nakagawa K
Hinyokika Kiyo; 1985 Mar; 31(3):377-86. PubMed ID: 4025077
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
Garcia JA; Mekhail T; Elson P; Wood L; Bukowski RM; Dreicer R; Rini BI
BJU Int; 2012 Jan; 109(1):63-9. PubMed ID: 21244601
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
